Group 1 - The core consumer demand during the Spring Festival is shifting from "face consumption" to "value consumption," with health becoming the primary consideration for 58% of consumers when selecting gifts [1][2] - There is a significant increase in health-related concerns among consumers, with 74% expressing health anxiety during the Spring Festival, driven by unhealthy eating and irregular schedules [2] - Functional products that meet precise health needs are rapidly penetrating the market, with plant-based beverages gaining popularity due to their natural attributes and health benefits [2][3] Group 2 - Yiling Health's product matrix effectively addresses both dining and gifting needs during the festival, particularly targeting consumers with specific health concerns such as blood sugar management [3] - The Tianliwang beverage, recognized for its health benefits and traditional Chinese medicine principles, has become a highlight for health-conscious consumers during the Spring Festival [3][4] - Yiling Health's integration of traditional Chinese medicine with modern technology has established a strong brand trust, supported by scientific validation and certifications [4]

Group 1 - The company’s subsidiary, Hengtai Wanyang Pharmaceutical, received approval for the chemical raw material drug Dapagliflozin, indicating compliance with national drug registration requirements [1] - Dapagliflozin is a selective SGLT-2 inhibitor used for treating type 2 diabetes by promoting glucose excretion [2] - China has over 118 million diabetes patients, accounting for 22% of the global burden, with the diabetes medication market projected to reach 52.7 billion yuan in 2024, where Dapagliflozin holds a 12.83% market share [3] Group 2 - The market for Dapagliflozin is expected to grow to 7.38 billion yuan in 2025, with a sales volume of 1.78 billion tablets, reflecting a year-on-year growth of 35% and 38% respectively [3] - Dapagliflozin has been included in the national centralized procurement directory, with a price reduction of over 90%, benefiting more patients [3] - The company plans to leverage this domestic approval to accelerate international registration and sales of Dapagliflozin, targeting markets in Europe and the US [3] Group 3 - The company’s subsidiary, Yiling Wanzhou International Pharmaceutical, received approval for the drug Valaciclovir, enhancing the company’s product pipeline [7] - Valaciclovir is an antiviral drug used for treating herpes zoster and simplex virus infections, with a market share of 3.17% in the antiviral drug market projected to reach 4.5 billion yuan in 2025 [9][10] - The increasing incidence of herpes zoster, especially among the aging population, is expected to drive demand for Valaciclovir [10] Group 4 - The company has submitted a clinical trial application for a new traditional Chinese medicine, Qilong Dingchuan Tablets, which has been accepted by the National Medical Products Administration [13] - The proposed indications for Qilong Dingchuan Tablets include treating chronic obstructive pulmonary disease with symptoms such as shortness of breath and cough [16]

Core Insights - Yiling Pharmaceutical has made significant progress in three therapeutic areas: antiviral, diabetes treatment, and respiratory diseases, reflecting its strategic expansion from traditional Chinese medicine to chemical drugs and innovative Chinese medicine [1][2] - The approval of the drug Acyclovir is expected to meet substantial market demand, with the antiviral drug market in China projected to reach 15.15 billion yuan in 2024, and Acyclovir products holding a 3.17% market share [1][2] - The diabetes medication Dapagliflozin is anticipated to grow significantly, with a market size of 52.7 billion yuan in 2024 and a projected 35% increase in market capacity by 2025 [2] - The clinical trial application for the traditional Chinese medicine Qilong Dingchuan Tablet has been accepted, targeting chronic obstructive pulmonary disease, which has a large patient population and unmet treatment needs [2] Group 1: Antiviral Drug Development - Yiling Pharmaceutical's Acyclovir is primarily used for treating herpes zoster and simplex virus infections, with a broad market demand as it is included in the National Basic Medical Insurance Drug List [1] - The market for antiviral drugs in China is expected to reach 15.15 billion yuan in 2024, with Acyclovir's market share projected to grow to 450 million yuan by 2025 [1][2] Group 2: Diabetes Treatment Expansion - Dapagliflozin is expected to capture a 12.83% market share in the diabetes medication market, with a projected market size of 7.38 billion yuan in 2025, reflecting a 35% year-on-year growth [2] - The drug has advantages in renal protection and cardiovascular benefits, and Yiling Pharmaceutical plans to accelerate its international registration and sales following domestic approval [2] Group 3: Traditional Chinese Medicine Innovation - The clinical trial application for Qilong Dingchuan Tablet has been accepted, targeting chronic obstructive pulmonary disease, which has a significant patient population and high unmet treatment needs [2] - The drug development process will proceed if no negative feedback is received within 60 days of acceptance [2] Group 4: Strategic Positioning and Risk Mitigation - The complementary product matrix formed by Acyclovir, Dapagliflozin, and Qilong Dingchuan Tablet enhances Yiling Pharmaceutical's resilience against policy and market competition risks [3] - The company's diversified pipeline and full industry chain layout are seen as effective strategies to mitigate risks in a tightening regulatory environment [3]

Core Viewpoint - Yiling Pharmaceutical has received approval from the National Medical Products Administration for the marketing authorization of its product, Valaciclovir Hydrochloride Tablets, through its wholly-owned subsidiary, Yiling Wanzhou International Pharmaceutical [1] Group 1 - Yiling Pharmaceutical's wholly-owned subsidiary, Yiling Wanzhou International Pharmaceutical, submitted a marketing authorization application for Valaciclovir Hydrochloride Tablets [1] - The approval from the National Medical Products Administration includes the issuance of a drug registration certificate [1]

以岭药业始终将ESG理念深度融入企业战略和日常经营。在环境保护方面，企业积极践行绿色发展战 略，通过推进节能减排、建设绿色工厂、创新绿色技术等一系列举措，助推低碳社会，展现了现代制药 企业的环保担当。在社会责任领域，以岭药业充分发挥医药企业专业优势，不仅致力于研发生产高品质 药品，为患者解除病痛，还积极参与公益事业，在捐资助教、助力乡村振兴、开展捐医送药等方面作出 积极贡献，彰显了企业的社会责任意识。在公司治理层面，以岭药业持续完善现代企业制度，强化合规 经营，注重股东权益保护，通过健全的治理结构和透明的信息披露，为可持续发展奠定了坚实基础。 据悉，榜单依托新浪财经ESG评级体系，以5000余家A股上市公司及在港上市内地企业为评价对象，搭 建18套行业ESG评价模型，对企业ESG表现进行综合、定量评价。评级体系基于企业可持续发展报告及 第三方数据等，纳入150余项ESG指标，得到企业ESG综合评级得分。排名位列前100的企业入选"上市 公司年度ESG百强榜"。 MACD金叉信号形成，这些股涨势不错！ MACD金叉信号形成，这些股涨势不错！ 登录新浪财经APP 搜索【信披】查看更多考评等级 近日，新浪财经重磅发 ...

Core Viewpoint - Yiling Pharmaceutical's wholly-owned subsidiary, Yiling Wanzhou, has obtained the registration certificate for Acyclovir Hydrochloride Tablets (0.5g), allowing it to sell in the domestic market [1]. Group 1: Approval Status - The product has been classified as a Class 4 chemical drug and is now qualified for domestic market sales [1]. Group 2: Product Information - Indications include treatment for shingles, herpes simplex virus infections, and prevention of recurrence [3]. - The product is included in the National Medical Insurance Directory as a Class B variety [3]. - The domestic market size for Acyclovir is expected to reach 450 million yuan by 2025, with a sales volume of 130 million tablets, capturing 3.17% of the antiviral drug market [3]. Group 3: Additional Information - The product is a dual-filing variety in both China and the U.S., having received FDA approval in March 2020 [2]. - The company notes that this product will not have a significant impact on current performance and emphasizes the need to monitor market policies and competitive risks [2].

Core Viewpoint - Yiling Pharmaceutical (002603.SZ) announced that its wholly-owned subsidiary, Hengtai Wanyang Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the marketing application of Dapagliflozin, a sodium-glucose co-transporter 2 (SGLT-2) inhibitor used for treating type 2 diabetes [1]. Group 1 - Yiling Pharmaceutical's subsidiary, Hengtai Wanyang, has successfully obtained a marketing approval for Dapagliflozin [1]. - Dapagliflozin is characterized as a highly selective and reversible SGLT-2 inhibitor that blocks glucose reabsorption in the renal proximal tubule, promoting urinary glucose excretion to lower blood sugar levels [1].

Group 1 - The core point of the article is that Yiling Pharmaceutical (002603.SZ) has received the Acceptance Notification from the National Medical Products Administration for its drug Qilong Dingchuan Tablets, which is intended for the treatment of chronic obstructive pulmonary disease (COPD) [1] Group 2 - The proposed indications for Qilong Dingchuan Tablets include invigorating qi, promoting blood circulation, resolving phlegm, stopping cough, and relieving asthma [1] - The drug is specifically aimed at patients with stable COPD characterized by symptoms such as shortness of breath, cough, and fatigue, among others [1]

Core Viewpoint - Yiling Pharmaceutical's wholly-owned subsidiary, Yiling Wanzhou International Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the marketing authorization application of Valaciclovir Hydrochloride Tablets, obtaining the drug registration certificate [1] Group 1 - Yiling Wanzhou has submitted a marketing authorization application for Valaciclovir Hydrochloride Tablets [1] - The approval from the National Medical Products Administration signifies a key milestone for the company [1] - The drug registration certificate allows the company to proceed with the commercialization of the product [1]

证券代码：002603 证券简称：以岭药业 公告编号：2026-002 石家庄以岭药业股份有限公司 关于全资孙公司收到化学原料药上市申请批准通知书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没 有虚假记载、误导性陈述或重大遗漏。 近日，石家庄以岭药业股份有限公司（以下简称"公司"）全资孙公司万洋衡 水制药有限公司（以下简称"衡水万洋"）收到国家药品监督管理局下发的《化 学原料药上市申请批准通知书》，由衡水万洋提交的"达格列净"化学原料药上市 申请已获批准。现就相关事项公告如下： 一、批准通知书基本内容 根据《中国糖尿病流行病学调查报告》显示，中国有超过 1.18 亿糖尿病患者， 占全球 22%的比例，为全球糖尿病负担最重的国家之一。根据米内网及药智网数 据显示，2024 年中国糖尿病用药市场规模达 527 亿元，其中达格列净市场份额占 12.83%。2025 年中国达格列净市场容量预计达 73.8 亿元，同比增长 35%；销售 量 17.8 亿片，同比增长 38%；2024 年中国达格列净原料药用度 17.48 吨，同比增 长 38.51%，销售呈现持续增长的趋势。达格列净被我国和 FD ...